{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:28:51Z","timestamp":1761766131390},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,11,29]]},"DOI":"10.18632\/oncotarget.13035","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T15:05:38Z","timestamp":1478185538000},"page":"79842-79853","source":"Crossref","is-referenced-by-count":19,"title":["Synergistic effects of selective inhibitors targeting the PI3K\/AKT\/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia"],"prefix":"10.18632","volume":"7","author":[{"given":"Carolina","family":"Simioni","sequence":"first","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Ultimo","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Zauli","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Milani","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"McCubrey","sequence":"additional","affiliation":[{"name":"Department of Microbiology & Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvano","family":"Capitani","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"},{"name":"LTTA Center, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca M.","family":"Neri","sequence":"additional","affiliation":[{"name":"Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/gcc.20743","article-title":"ABL1 rearrangements in T-cell acute lymphoblastic leukemia","volume":"49","author":"Graux","year":"2010","journal-title":"Genes, chromosomes & cancer"},{"key":"2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1535-6108(02)00018-1","article-title":"Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia","volume":"1","author":"Look","year":"2002","journal-title":"Cancer Cell"},{"key":"3","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbior.2014.04.004","article-title":"Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells","volume":"56","author":"Chiarini","year":"2014","journal-title":"Adv Biol Regul"},{"key":"4","first-page":"1116","article-title":"Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia","volume":"90","author":"Cools","year":"2005","journal-title":"Haematologica"},{"key":"5","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/sj.leu.2403595","article-title":"e6-a2 BCR-ABL1 fusion in T-cell acute lymphoblastic leukemia","volume":"19","author":"Drexler","year":"2005","journal-title":"Leukemia"},{"key":"6","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/ng1425","article-title":"Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia","volume":"36","author":"MacLeod","year":"2004","journal-title":"Nature genetics"},{"key":"7","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/blood-2004-12-4897","article-title":"Fusion of EML1 to ABL1 in T-cell acute lymphoblastic leukemia with cryptic t(9;14) (q34;q32)","volume":"105","author":"Cools","year":"2005","journal-title":"Blood"},{"key":"8","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Matter","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"9","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1073\/pnas.91.4.1519","article-title":"The human CAN protein, a putative oncogene product associated with myeloid leukemogenesis, is a nuclear pore complex protein that faces the cytoplasm","volume":"91","author":"Radu","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3892\/ol.2014.2263","article-title":"NUP214 fusion genes in acute leukemia (Review)","volume":"8","author":"Yang","year":"2014","journal-title":"Oncol Lett"},{"key":"11","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1038\/leu.2008.80","article-title":"Activity of tyrosine kinase inhibitors against human NUP214-ABL1-positive T cell malignancies","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1016\/j.leukres.2011.03.025","article-title":"NUP214-ABL1 positive T-cell acute lymphoblastic leukemia patient shows an initial favorable response to imatinib therapy post relapse","volume":"35","author":"Cooney","year":"2011","journal-title":"Leuk Res"},{"key":"13","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.3816\/CLM.2007.s.012","article-title":"Bcr-Abl kinase domain mutations and the unsettled problem of Bcr-Abl(T315I): Looking into the future of controlling drug resistance in chronic myeloid leukemia","volume":"7","author":"Deininger","year":"2007","journal-title":"Clin Lymphoma Myelom"},{"key":"14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Liu","year":"2013","journal-title":"J Med Chem"},{"key":"15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","article-title":"Development of PI3K inhibitors: lessons learned from early clinical trials","volume":"10","author":"Tabernero","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"16","first-page":"108","article-title":"Targeting the PI3K\/mTOR Pathway in Pediatric Hematologic Malignancies","volume":"4","author":"Rheingold","year":"2014","journal-title":"Front Oncol"},{"key":"17","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/leu.2008.278","article-title":"Heterogeneous patterns of amplification of the NUP214-ABL1 fusion gene in T-cell acute lymphoblastic leukemia","volume":"23","author":"Simons","year":"2009","journal-title":"Leukemia"},{"key":"18","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/onc.2010.561","article-title":"Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis","volume":"30","author":"Rathmell","year":"2011","journal-title":"Oncogene"},{"key":"19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/blood-2006-10-050260","article-title":"Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance","volume":"110","author":"Cleveland","year":"2007","journal-title":"Blood"},{"key":"20","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/leu.2008.242","article-title":"Intrinsic differences between the catalytic properties of the oncogenic NUP214-ABL1 and BCR-ABL1 fusion protein kinases","volume":"22","author":"Hantschel","year":"2008","journal-title":"Leukemia"},{"key":"21","doi-asserted-by":"crossref","first-page":"e133","DOI":"10.3324\/haematol.2015.136499","article-title":"NUP214-ABL1 fusion defines a rare subtype of B-cell precursor acute lymphoblastic leukemia that could benefit from tyrosine kinase inhibitors","volume":"101","author":"Preudhomme","year":"2016","journal-title":"Haematologica"},{"key":"22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1756-8722-4-6","article-title":"BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance","volume":"4","author":"Drexler","year":"2011","journal-title":"J Hematol Oncol"},{"key":"23","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.ejca.2015.07.018","article-title":"Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia","volume":"51","author":"Favaro","year":"2015","journal-title":"Eur J Cancer"},{"key":"24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/leu.2013.349","article-title":"Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling","volume":"28","author":"McCubrey","year":"2014","journal-title":"Leukemia"},{"key":"25","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1038\/leu.2013.369","article-title":"Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia","volume":"28","author":"McCubrey","year":"2014","journal-title":"Leukemia"},{"key":"26","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1172\/JCI34616","article-title":"PTEN posttranslational inactivation and hyperactivation of the PI3K\/Akt pathway sustain primary T cell leukemia viability","volume":"118","author":"Barata","year":"2008","journal-title":"J Clin Invest"},{"key":"27","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/pbc.22710","article-title":"Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program","volume":"55","author":"Lock","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"28","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.cellsig.2011.05.004","article-title":"Akt signalling in health and disease","volume":"23","author":"Tavare","year":"2011","journal-title":"Cell Signal"},{"key":"29","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.canlet.2014.02.025","article-title":"Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase\/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines","volume":"347","author":"Koizumi","year":"2014","journal-title":"Cancer Lett"},{"key":"30","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Baselga","year":"2012","journal-title":"Annals Oncol"},{"key":"31","doi-asserted-by":"publisher","first-page":"17147","DOI":"10.18632\/oncotarget.3940","article-title":"The novel dual PI3K\/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells","volume":"6","author":"Neri","year":"2015","journal-title":"Oncotarget"},{"key":"32","doi-asserted-by":"publisher","first-page":"19897","DOI":"10.18632\/oncotarget.7658","article-title":"ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells","volume":"7","author":"Kong","year":"2016","journal-title":"Oncotarget"},{"key":"33","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1158\/1541-7786.MCR-08-0366","article-title":"Targeting melanoma with dual phosphoinositide 3-kinase\/mammalian target of rapamycin inhibitors","volume":"7","author":"Wymann","year":"2009","journal-title":"Mol Cancer Res"},{"key":"34","doi-asserted-by":"crossref","first-page":"13577","DOI":"10.3390\/ijms140713577","article-title":"antimetastatic effect of phosphatidylinositol 3-kinase inhibitor ZSTK474 on prostate cancer PC3 cells","volume":"14","author":"Kong","year":"2013","journal-title":"Intl J Mol Sci"},{"key":"35","first-page":"95","article-title":"Torin2 Potentiates Anticancer Effects on Adult T-Cell Leukemia\/Lymphoma by Inhibiting Mammalian Target of Rapamycin","volume":"36","author":"Sueoka","year":"2016","journal-title":"Anticancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3892\/or.2015.4146","article-title":"The novel mTOR inhibitor Torin-2 induces autophagy and downregulates the expression of UHRF1 to suppress hepatocarcinoma cell growth","volume":"34","author":"Pan","year":"2015","journal-title":"Oncol Rep"},{"key":"37","doi-asserted-by":"crossref","first-page":"466","DOI":"10.2119\/molmed.2014.00238","article-title":"Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer","volume":"21","author":"Al-Kuraya","year":"2015","journal-title":"Mol Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0609.2011.01586.x","article-title":"ABL1 fusion genes in hematological malignancies: a review","volume":"86","author":"De Braekeleer","year":"2011","journal-title":"Eur J Haematol"},{"key":"39","doi-asserted-by":"crossref","first-page":"e83510","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2","volume":"8","author":"Quentmeier","year":"2013","journal-title":"PloS one"},{"key":"40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","article-title":"Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia","volume":"371","author":"Rusch","year":"2014","journal-title":"N Eng J Med"},{"key":"41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4161\/auto.22259","article-title":"BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide","volume":"9","author":"Platanias","year":"2013","journal-title":"Autophagy"},{"key":"42","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.18632\/oncotarget.762","article-title":"A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia","volume":"3","author":"Martinelli","year":"2012","journal-title":"Oncotarget"},{"key":"43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J Immunol Methods"},{"key":"44","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.4161\/cc.29267","article-title":"Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia","volume":"13","author":"Martelli","year":"2014","journal-title":"Cell Cycle"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T10:08:28Z","timestamp":1718878108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,3]]},"references-count":44,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2016,11,29]]}},"alternative-id":["13035","27821800"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13035","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,3]]}}}